A Randomized Phase II Trial of Thalidomide, an Angiogenesis Inhibitor, in Patients with Androgen-independent Prostate Cancer

Purpose: Thalidomide is a potent teratogen that causes dysmelia in humans. Recently, in vitro data suggested that it inhibits angiogenesis. Prostate cancer is dependent on the recruitment of new blood vessels to grow and metastasize. Based on those data, we initiated a Phase II trial of thalidomide...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2001-07, Vol.7 (7), p.1888-1893
Hauptverfasser:	FIGG, William D, DAHUT, William, CHEN, Clara C, DIXON, Shannon, KOHLER, David R, KRÜGER, Erwin A, GUBISH, Ed, PLUDA, James M, REED, Eddie, DURAY, Paul, HAMILTON, Michael, TOMPKINS, Anne, STEINBERG, Seth M, JONES, Elizabeth, PREMKUMAR, Ahalya, LINEHAN, W. Marston, FLOETER, Mary Kay
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Androgens - physiology Angiogenesis Inhibitors - therapeutic use Antineoplastic agents Biological and medical sciences Chemotherapy Dose-Response Relationship, Drug Endothelial Growth Factors - blood Fibroblast Growth Factor 2 - blood Fibroblast Growth Factor 2 - drug effects Follow-Up Studies Humans Lymphokines - blood Lymphokines - drug effects Lymphotoxin-alpha - blood Male Medical sciences Middle Aged Mood Disorders - chemically induced Neovascularization, Pathologic - pathology Neutropenia - chemically induced Pharmacology. Drug treatments Prostate-Specific Antigen - blood Prostate-Specific Antigen - drug effects Prostatic Neoplasms - blood supply Prostatic Neoplasms - drug therapy Prostatic Neoplasms - pathology Survival Analysis Thalidomide - therapeutic use Time Factors Treatment Outcome Tumor Necrosis Factor-alpha - drug effects Tumor Necrosis Factor-alpha - metabolism Vascular Endothelial Growth Factor A Vascular Endothelial Growth Factors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!